Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neumora Therapeutics, Inc. (NMRA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Neumora uses current reports on Form 8-K and other filings to communicate material information about its financial condition, capital structure and key pipeline events.
In recent 8-K filings, Neumora has reported quarterly financial results, including details on research and development and general and administrative expenses, net loss and cash, cash equivalents and marketable securities. These filings also reference the company’s expectation that its available capital will fund its operating plan into 2027, based on the specific reporting dates. Other 8-Ks describe business updates such as the initiation of a Phase 1 SAD/MAD study of NMRA-898, a positive preclinical data announcement for NMRA-215, and the associated press releases furnished or filed as exhibits.
Neumora has also filed an 8-K describing a conversion under its Loan and Security Agreement with K2 HealthVentures LLC, in which a portion of the outstanding term loan principal was converted into shares of common stock. This filing outlines the conversion terms, the number of shares issued and the reliance on a registration exemption under the Securities Act of 1933.
On Stock Titan, Neumora’s SEC filings are updated as they appear on EDGAR, and AI-powered summaries help explain the key points in plain language. Users can review current reports on Form 8-K for material events, track changes related to financing arrangements, and connect these disclosures with the company’s broader clinical and business narrative. This page is a resource for understanding how Neumora reports its financial results, capital transactions and significant pipeline milestones to regulators and investors.